Ibandronic acid Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0026 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
05/01/2023 
SmPC and PL 
To update section 4.8 of the SmPC to add the adverse 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
reaction hypocalcaemia with a frequency uncommon as 
assessed for reference product. The Package leaflet is 
updated accordingly.  
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IB/0025 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/04/2022 
20/12/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0024 
A.7 - Administrative change - Deletion of 
22/12/2021 
20/12/2022 
Annex II and 
manufacturing sites 
PL 
IB/0023/G 
This was an application for a group of variations. 
29/09/2021 
n/a 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
IB/0022 
B.II.b.3.a - Change in the manufacturing process of 
19/10/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0021 
B.II.b.2.c.1 - Change to importer, batch release 
08/07/2020 
24/06/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0020/G 
This was an application for a group of variations. 
16/12/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0019 
B.II.b.2.a - Change to importer, batch release 
28/08/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0017 
B.II.b.3.a - Change in the manufacturing process of 
18/07/2019 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
T/0016 
Transfer of Marketing Authorisation 
01/02/2019 
20/02/2019 
SmPC, 
Labelling and 
PL 
IAIN/0015/G 
This was an application for a group of variations. 
12/10/2018 
20/02/2019 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0014 
B.II.e.3.b - Change in test procedure for the 
27/07/2018 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
R/0013 
Renewal of the marketing authorisation. 
20/07/2017 
18/09/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Ibandronic acid Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0012 
A.7 - Administrative change - Deletion of 
17/01/2017 
18/09/2017 
Annex II and 
manufacturing sites 
PL 
IB/0011/G 
This was an application for a group of variations. 
20/06/2016 
12/08/2016 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0010/G 
This was an application for a group of variations. 
18/03/2016 
n/a 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/09/2015 
12/08/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
X/0006 
To add a new strength/potency and a new 
22/01/2015 
23/03/2015 
SmPC, Annex 
pharmaceutical form 3 mg solution for injection. 
Annex I_2.(c) Change or addition of a new 
strength/potency 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
II, Labelling 
and PL 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/07/2014 
23/03/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0007 
B.I.b.1.z - Change in the specification parameters 
15/04/2014 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IA/0005/G 
This was an application for a group of variations. 
10/03/2014 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0004 
B.II.b.2.a - Change to importer, batch release 
12/11/2013 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0003 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/05/2013 
08/01/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
IAIN/0001/G 
This was an application for a group of variations. 
03/01/2013 
08/01/2014 
Annex II and 
PL 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
